Finally, tumor accumulation experiments indicated that, the uptake in the tumor masses 24 h after the injection of the c-Src inhibitor, was significantly superior in NB-bearing mice receiving Si306 encapsulated into GD2-LP[Si306], compared with that obtained in mice treated with either free Si306, or Si306 encapsulated in untargeted LP (Figure 6), indicating the importance of the active targeting, via the GD2 receptor, for the subsequent therapeutic experiments. The gene discussed is SRC; the disease is neuroblastoma.